Docetaxel liposomal - Cytori

Drug Profile

Docetaxel liposomal - Cytori

Alternative Names: ATI-1123; AZD 1123; CAN-001

Latest Information Update: 18 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Azaya Therapeutics
  • Developer Azaya Therapeutics; Cytori Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Feb 2017 Phase-I clinical trials in Solid tumours in USA (IV)
  • 15 Feb 2017 Azaya Therapeutics has been acquired and merged into Cytori Therapeutics
  • 19 Jan 2017 Cytori Therapeutics enters into a definitive agreement with Azaya Therapeutics for the proposed acquisition of Azaya Therapeutics assets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top